Dapagliflozin Cuts Heart Risk in T2D With Advanced Fibrosis

Published Date: 08 Jul 2026

Dapagliflozin can reduce the risk for major adverse cardiovascular events in patients with T2D at a high risk for advanced liver fibrosis, according to a retrospective study.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot